Translation of scientific bench-top discoveries into a commercial enterprise can be one of the hardest transitions for academic groups. Additionally, there are very few therapeutic options for neurodegenerative diseases, and a great need exists for the development of new drug candidates to treat diseases, such as amyotrophic lateral sclerosis. Our proposal seeks to continue with the development of new neurodegenerative therapeutics, while simultaneously analyzing and developing commercialization strategies for the translation of drug discoveries into start-up enterprises. Specifically, our proposal seeks to continue with the development of our new ALS therapeutics, using animal models of the disease, while also devising a commercialization strategy for translation of the intellectual property generated as part of this project.